Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Finland
Sweden
Denmark
Norway
Latest
Trending
Followed

Egetis Therapeutics, Audiocast, Q1'26

By Inderes4/29/2026, 8:00 AM
Egetis Therapeutics

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Nicklas Westerholm
00:01 - 04:14

Good morning and a warm welcome to our Quarter 1 results presentation for the coming 30 minutes. This is for those who haven't had the privilege to meet before. My name is Nicklas Westerholm and the CEO of the company. With me today we also have Yilmaz Mahshid, Chief Financial Officer, Henrik Krook, Vice President, Commercial Operations and President of our U.S. business, and Karl Hård, Vice President and Head of Investor Relations. Let's turn our attention to the topics covered today depicted on the slide in front of you. To summarize, Quarter 1 has been historical for Egetis. This quarter included several key milestones delivered, among others and most importantly, the FDA acceptance of our New Drug Application for Emcitate® for the treatment of MCT8 deficiency, where the agency also granted us a Priority Review with a PDUFA target action date, a decision date set to September 28th, 2026. We will also provide an update on the launch preparations in the US, as well as the commercialization in the European Union, and furthermore, the financial update will be covered by our CFO and we aim to leave ample time for Q&A at the end of the session. So let's turn our attention to the highlights of the quarter. The very strong execution continued in Quarter 1, building on the great momentum in 2025 and positioning us well for the U.S. Launch in Quarter 4 this year, we completed the US New Drug Application, i.e. NDA for Emcitate® in January. Then the NDA was accepted by the FDA on the 27th of March. We were also granted a Priority Review and a PDUFA target action date set to the 28th of September. Furthermore, the agency stated that it is not currently planning to hold an advisory committee meeting to discuss our application. So all in all, this is a major achievement and represents an important step in making Emcitate available to MCT8 deficiency patients in the US, with an expected launch in Quarter 4 this year. Furthermore, in March, the US Patent and Trademark Office issued a notice of allowance for an MCT8 deficiency composition patent. The allowed claims cover, among other things, a method of treating MCT8 deficiency with a pharmaceutical composition encompassing tiratricol, including dosing regimens and a tiratricol composition with specific exceptions. This represents a significant milestone in strengthening our intellectual property, and we expect the resulting patent to be listed in the Orange Book with an anticipated expiration date in 2045. Last but not least. In April, we successfully carried out an oversubscribed directed share issue amounting to 350 million Swedish crowns. The issue was priced at 525 Swedish krona per share, corresponding to zero discount to market close and more importantly, with very strong participation from new and existing investors focused on US biotech investors like Frazier Life Sciences, Invus, Woodline Partners and Parkman Healthcare Partners. This means that we are now well placed to execute on our strategy of progressing our lead asset Emcitate through US approval and launch. And with that, I will now now hand over to Annie Bedard to provide an update on our launch preparations in the US, our most important market. Annie, please.

Unknown 1
04:15 - 09:14

Good day everyone. Let's now turn to the United States, our most important commercial market and a key driver of long-term growth. As Nick said, the US launch is on track for Q4 2026, and this is supported by expanding patient identification, increasing experience with tiratricol in early access program, and continued progress on market access readiness, starting with patient identification. We've now identified more than 140 genetically confirmed patients, and that number continues to grow each quarter. Our field medical team is now fully deployed, engaging specialist centers that are central to patient identification and treatment. They're engaging with physicians across endocrinology, neurology, and clinical genetics, with the focus on centers already managing known patients, increasing disease awareness, and enabling meaningful clinical dialogue, and accelerating diagnosis and referral pathways. We're also expanding our presence at key scientific meetings, including the American College of Medical Genetics, which took place in the first quarter, and the Pediatric Endocrine Society, which is taking place this week and is our most important meeting. These engagements are critical to connecting with healthcare professionals, sharing emerging data, advancing the earlier recognition and diagnosis of MCT8 deficiency. Just as importantly, we continue to build strong relationships with the MCT8 caregiver and advocacy community. This engagement helps us better understand the patient journey, incorporate caregiver perspectives, inform our plans, and strengthen the trust with the families. Our US Early Access program continues to expand. With 50 patients now receiving treatment across 20 specialist centers. This program enables access for patients with significant unmet need while also providing physicians with real-world experience managing tiratricol. These insights are helping us inform our implementation approach, deepen engagement with specialist centers, and better define the support that will be required for both patients and providers; over time, we are also making solid progress in building the access and patient support infrastructure that is needed for launch. Our work has now moved from implementation to execution, with national account directors now engaging Medicaid and commercial payers to communicate the seriousness of the disease, the lack of approved treatment options, and to strengthen our clinical and real-world evidence. In parallel, we've selected our three 3PL and specialty pharmacy partners, and we're advancing our patient support program, which will include the specialty pharmacy integration, benefit verification, and the patient services to ensure that we have seamless access for both patients and physicians from day one. Finally, we're building the team to deliver on this opportunity. We're establishing a US organization led by experienced rare disease experts across medical affairs, market access and commercial, with a strong track record in rare disease and first-in-class launches. Over the past quarter, we've continued to expand these functions to ensure launch readiness, and we remain on track to reach approximately 25 US colleagues at launch. We believe this is the right scale to capture the opportunity while maintaining capital discipline. So together, this progress is translating into strong launch readiness. We're gaining greater visibility into the patient population, seeing strong engagement from specialists. We're addressing the needs of patients with high unmet medical need, with tiratricol and having constructive early discussions with payers. This supports our confidence in a successful launch at approval and over time, establishing tiratricol as the standard of care with MCT8 Deficiency. Thanks for your attention, and I'll now turn it over to Henrik for an update on commercialization in Europe.

Operator
09:16 - 13:05

Thank you, Anny, and good morning everyone in Europe and for our international business. We continue to build momentum heading into the year, supported by increasing patient identification, expanding access, and a broader geographic footprint. In Q1, Emcitate revenue was 13.4 million. This was 9% higher than Q1 2025 at constant exchange rates, but lower than Q4 2025. The difference versus Q4 was primarily for two reasons. Normal fluctuations in ordering patterns and accrual of rebates in Germany as we await the final reimbursed price. Importantly, these factors affect the timing of recognized sales in the quarter. They do not change our view of the substantial medical need or the momentum we are seeing. Overall, the commercial fundamentals continue to move in the right direction with more identified patients and increasing contribution from a broader set of countries and prescribers. With that, we expect the Q2 revenue numbers to be higher than the Q1 numbers. Then briefly, on Germany, the pricing and reimbursement process is progressing, and we expect it to conclude in Q2. We continue to develop the market through disease awareness, physician engagement, Congress presence, and education. In February, we launched a web-based, certified continuous medical education program focused on MCT8 deficiency. And during the quarter, we exhibited at four scientific congresses across Germany and Austria. Over the past year, several new patients have been identified in Germany, with patients progressively moving to treatment initiation. Beyond Germany, we are expanding access across additional European markets in France, Spain, and Italy. We are advancing the national pricing and reimbursement dossiers for upcoming submissions over the next months. In parallel with these national pricing and reimbursement processes, we have successfully established regionally reimbursed routes in Spain and Italy that we can leverage until the national processes have concluded. In Q1, we generated our first sales revenue in Italy through this regionally reimbursed pathway. We have also successfully implemented alternative reimbursement solutions in certain additional countries, including Switzerland and Austria, ensuring access and helping generate revenue. We also see growing reach through our distribution partners. We are supported by a team in Turkey plus central, eastern and Southeastern Europe and by taiba rare in the Gulf region. Er-Kim and Taiba Rare are actively identifying patients and initiating processes aiming for funded treatment, which contributed to nine patient sales revenue in Poland and Turkey in the quarter. In addition to our existing distribution partnerships, we remain in active dialogue with potential partners to extend access in additional geographies over time. And with that, I would like to hand over to our CFO, Yilmaz Mahshid.

Nicklas Westerholm
13:07 - 16:01

Thank you, Henrik. To start, all numbers on this call are in the operating currency, Swedish Krona. Revenue for the first three months was 13.4 million versus 12.7 million in the same period last year, corresponding to a year over year growth of 9% in constant exchange rates. As you can see, the gross profit is -0.2 million. This is due to the continued depreciation of intangible R&D, a non-cash item totaling 10.1 million for the quarter. Gross profit would have been 9.9 million, corresponding to an adjusted gross margin of approximately 74%. Q1 2026 operating results were -92.9 million versus -62.9 million. In the prior period, the lower results are due to our continued investments and work with the US NDA, US commercial buildup, and corresponding pre-launch activities. The management, the board and our main shareholders are aligned that investing in the US is a key priority, as we believe this will be by far our most important market and where we need to be successful. I would also like to highlight, despite our higher year-over-year cost base, our total operating expenses are sequentially down by approximately 32 million. Almost all the lower cost base is R&D related, and specifically to all the costs that were taken for the wind down of the ReTRIACt study and the hard and intensive work conducted by the team for the US NDA in Quarter 4. For the first quarter, cash flow from operating activities was at -64.3 million versus -66.1 million. We ended the quarter with a cash position of 142.5 million, and it was gratifying to see that we did strengthen the cash position. Further, on April 21st, we raised 350 million on a gross basis. The high demand for the shares offered was depicted by the fact that they printed at a share price of 5.25, corresponding to a zero discount to the market close on the same day. The interest to participate came largely from foreign specialist and long only investors such as Frazier Life Sciences, Invus, Woodline Partners, and Parkman Healthcare Partners, but also from the Swedish healthcare specialist Linc AB. These investors have great insights into the US pharmaceuticals market and what it takes to succeed there. With that, I am back to Nicklas.

Unknown 1
16:02 - 17:12

Thank you. So let's turn our attention to the future. Looking ahead, we have a very exciting period ahead of us. We have the due date set by the US FDA for the 28th of September, and upon approval, we expect to be granted a Priority Review Voucher, which we will likely monetize in Quarter 4. Of note here is that PRVs sold in 2025 and 2026 have fetched in the region of 150 to 200 million USD each. Furthermore, and as mentioned before, we expect the launch of Emcitate in the US in quarter four. And in parallel with that, we're going to prepare and drive forward indication expansion into resistance to thyroid hormone beta. Our next pipeline opportunity. So with that, all in all, a very successful quarter and a very exciting period ahead of us. I will now hand over to the operator for questions and answers. Operator, please go ahead.

Operator
17:14 - 17:39

If you wish to ask a question, please dial Pound Key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial Pound Key six on your telephone keypad. The next question comes from Chiara Montone from Van Kempen. Please go ahead.

Nicklas Westerholm
17:41 - 18:17

Hi. Good morning. Congrats on the successful quarter and thank you for taking my question. I have a couple, if I may. So the first one would be, any update on when we can expect the publication of the survival data by Erasmus? Do you expect that to be before the date in September and another one will be around RTH-beta? So I was wondering, how are you thinking about the design of this trial and the timing and any learning from methods that you can directly apply to RTH-beta? Thank you.

Unknown 1
18:18 - 20:26

Thank you Chiara, and good morning and also grateful that you acknowledged our very successful quarter. So the first question you had was around the publication of the so-called survival data. The survival data formed a vital part of the NDA submission to the US FDA. There is some hope the audience will appreciate that the survival data is owned by the Erasmus Medical Center, and subsequently they are directing the upcoming publication. What we know and what I can share is that the manuscript has been completed and submitted to a high-profile journal, and it's out for review, so I don't have any further insights than that, but hopefully it will be published in the not too distant future. Then, when it comes to RTH-beta, Chiara, we're very excited about this opportunity. It's a substantial unmet medical need. Also, in this patient population, no treatment exists. Here we have actually started, together with key opinion leaders, discussing a design of a pivotal study. That is important, recognizing that the safety data we have generated today in MCT8 deficiency will be supportive also of an RTH-beta opportunity, driven by very much similar dosing. So the next step here is to conclude the design of a pivotal study. As I'm sure you have seen, Chiara, we have a new incoming CMO. This will be his first task, with the ambition to finalize the study design towards the end of the summer, and subsequently engage with both EMA and FDA to agree on an endpoint in such a study. Ambition is to start a pivotal study at some point during 2027. Thank you, Chiara.

Operator
20:28 - 20:33

The next question comes from Arvid Nicator from NTB Carnegie. Please go ahead.

Nicklas Westerholm
20:35 - 21:33

Good morning, guys, and thanks for taking my questions. So the first one on sales, I was just wondering if you can provide a little bit more granularity on the factors contributing to the quarter-on-quarter decrease. And then just on the full year sequencing, you said you expect higher sales in Q2, assuming that reimbursement is achieved at an adequate level in Germany. You expect an initial stocking up effect at centers that are already up and running with MCT8 deficiency programs, or should we expect a more linear sequential growth through 2026? And second one on R&D cost, if I may, how much is left to pay off from the ReTRIACt study and with recent capital raise intended to support the development of RTH-beta? Can you comment on what you are budgeting for in terms of costs for this in 2026? I'll start there. Thanks.

Unknown 1
21:33 - 22:52

No thank you. Are we done? And great to have you on the call. You have two questions. One around the European commercialization and the performance there and expectations in the future. And the second one was, to my understanding, around R&D costs and potential additional payments for the closing down of the ReTRIACt withdrawal study. I'll start off with European commercialization, as I'm sure you appreciate. We have seen a slight decrease quarter on quarter when it comes to revenue. As Henrik mentioned, this is very much driven by variation in payments. All the accruals as well. Excuse me, as accruals for rebates for the upcoming final price in Germany. As Henrik mentioned, the pricing and reimbursement discussion is progressing well, and we expect an outcome of that in Quarter 2. And we also mentioned, as you rightly said, that we expect an increase in Quarter 2 versus Quarter 1 from a revenue perspective. This is very much driven by the totality of our partnership. Our partnership in the Turkey and Gulf region, and Central, Eastern, and Southern Eastern Europe, is bearing fruit. And we expect an increase in overall demand there. But I'll hand over to Henrik to provide somewhat more granularity to what I just said.

Operator
22:52 - 23:27

Yeah, I think you covered it well, Nicklas, and I think it's important to see that our view on the underlying demand is the same. There is a substantial medical need, and the momentum we see in the market is positive. So, overall, the commercial fundamentals continue to move in the right direction with more identified patients and increasing contribution from more prescribers. So, overall, positive outlook moving forward.

Nicklas Westerholm
23:27 - 23:31

Thank you, Henrik. And then we had a question around R&D costs. Yilmaz. Yes.

Unknown 1
23:31 - 23:51

Hi. Thanks for the question. No, we don't have so much cost left for the wind down of the ReTRIACt studies. Pretty much negligible going forward. From here, most of the activities will be related to the NDA filing in the US and starting the work with RTH-beta at these levels.

Nicklas Westerholm
23:54 - 24:01

Thank you, Yilmaz, and thank you for your questions. Operator, the next question, if you don't mind.

Unknown 1
24:02 - 24:07

The next question comes from Oscar Haven Lamb from Stifel. Please go ahead.

Operator
24:09 - 24:22

Hi, team. Thanks for taking my question. In Germany, how confident are you that the final negotiated price will come in line with your expectations? Are there different scenarios that we could expect?

Nicklas Westerholm
24:23 - 24:52

Well, I think. Sorry, Oscar. Thank you for the good question. Obviously, we don't give any guidance on our assumptions. As always in Europe nowadays, there is a challenging environment across all more or less countries when it comes to pricing and reimbursement. We have adequately accrued for what we believe would be a reasonable rebate in line with industry standards. That said, I can't share any more details.

Operator
24:56 - 25:21

Understood. Then, perhaps a quick follow-up, since we are still on the topic of Germany. We're now almost a year after your commercial launch. How would you say it's tracking since you've started on its initial timeline? Is it in line with your expectations? How is it dynamic in terms of patient satisfaction, how they are taking in the product, etc.?

Nicklas Westerholm
25:21 - 26:04

I think, and again, it's in line with our expectations. But bearing in mind that our expectations have also always been based on the reality of how it works in Europe today, where both pricing and reimbursement discussions and other components are tough. But as we mentioned before, within a quarter we effectively converted all the patients in our managed access program into commercial product. On top of that, as I'm sure we have discussed before. We also identified quite a few additional patients where we have also managed to get a few of them on therapy. So I think, all in all, it is progressing in the right direction. But Henrik, you might want to add some more color to this.

Operator
26:04 - 27:13

Thank you, Nicklas, and I agree that I think it's in line with our expectation. Overall, Germany is a little bit of a challenging environment. And that is also something that we hear from our networks at other pharma companies. There is a high workload on specialists involved in rare diseases. So this means that it is difficult for the pharma industry to get appointments with physicians, and more importantly, that it also can be difficult for new patients to get appointments with the right specialist within a short time frame. So this is unfortunate for some patients because it can result in slower initiation of new treatment. But overall, it's moving in the right direction. And it's important to note that for patients who have initiated treatment, the adherence to treatment has been very high. Both caregivers and physicians have expressed positive feedback regarding treatment effects.

Nicklas Westerholm
27:14 - 27:43

Thank you so much, Henrik. And that takes us to the end of the call today. I would just like to thank the participants and for the insightful questions during the call. And again, as depicted on the slide here in front of us, we have a very exciting period ahead of us with several key value-enhancing milestones. Thank you everybody, and I wish you a great rest of the day.

Continue to the webcast
Revenio Group Oyj, Q3'26
Language: English11/12/2026, 1:00 PM
Jukka Kainulainen Good afternoon, and welcome to the Revenio Group Corporation Q3 Earnings Call. My name is Jouni Toijala. I am the CEO. And then, again today we have Jukka Kainulainen, our CFO, on th…
Kamux, Q3'26
Language: English11/12/2026, 9:00 AM
Katerina Heterant Good morning. Welcome to the Kamux Q3 results presentation. My name is Katerina Heterant and I am Head of Investor Relations at Kamux. Today we shall go through the Q3 results presen…
Koskisen, Webcast, Q3'26
Language: Finnish11/12/2026, 8:00 AM
Jukka Pahta Hyvää huomenta ja tervetuloa tähän osavuosikatsaustilaisuuteen! Koskisen tammi–syyskuun osavuosikatsaustilaisuuteen lähdetään otsikolla: Koskisen liikevaihdon kasvu jatkui. Kohonneet kusta…
Reaktor, Q3'26
Language: Finnish11/11/2026, 9:00 AM
Pekka Horo Oikein hyvää aamupäivää kaikille ja tervetuloa tähän meidän webcastiimme. Olen Pekka Horo, Reaktorin toimitusjohtaja, ja kanssani täällä on tänään Antti Akkanen, joka aloitti lokakuussa Rea…
Savox, Q3'26
Language: English11/10/2026, 11:00 AM
Paulina Tanila Our speakers today are CEO Jerry Kettunen and CFO Juha Järvi. Jerry will give an overview of Savox as a company and go through the highlights of the quarter. After that, Juha will conti…
Raisio Oyj, Webcast, Q3'26
Language: Finnish11/10/2026, 10:00 AM
Elli Siltala Hyvää marraskuista päivää Raisiosta! Ja tervetuloa Raision tammi-syyskuun 2026 osavuosikatsauksen webcastiin! Pahoittelut pienistä teknisistä haasteista, mitä meillä oli tässä alussa. Min…
Mandatum Oyj, Audiocast, Q3'26
Language: English11/10/2026, 9:00 AM
Lotta Borgström Good morning, everyone, and welcome to the Mandatum Q3 2026 audiocast. My name is Lotta Borgström from Investor Relations. Joining me today are our CEO, Petri Niemisvirta, and our CFO,…
Solar foods Go-to-market Update
Language: English11/9/2026, 12:00 PM
Maria Hello everyone, and welcome to the Solar Foods go-to-market update. My name is Maria and I'm here today with our CEO, Rami Jokela, and CFO and Deputy CEO, Ilkka Saura. Also with us today is Heli…
Outokumpu, Webcast, Q3'26
Language: English11/6/2026, 12:30 PM
Johan Welcome to the third quarter results webcast. I am responsible for investor relations. We will start with the presentation from our CEO, Kati ter Horst, and our CFO, Marc-Simon Schaar. After the…
Endomines, Webcast, Q3'26
Language: English11/5/2026, 1:00 PM
Andy Turpin Hello, everyone, and welcome to Endomines' third-quarter results webcast. Thanks for joining us today. My name is Andy Turpin and I am the Chief Communications Officer here at Endomines. A…
Lemonsoft Oyj, Q3'26 webcast
Language: English11/5/2026, 11:00 AM
Unknown 1 Welcome to the Lemonsoft Q3 results presentation. We will start with the presentation from CEO Alpo Luostarinen, followed by the Q&A. You can send your questions throughout the event via the…
Enersense, Webcast, Q3'26
Language: English11/5/2026, 10:30 AM
Liisa Tamminen Hello and welcome to the Enersense Q3 2026 results webcast. My name is Liisa Tamminen from Enersense Investor Relations. And with me here I have our CEO, Kari Sundbäck, and CFO, Jan-Elo…
Sitowise, Q3'26
Language: English11/5/2026, 10:00 AM
Mari Reponen Good day everyone, and welcome to the Sitowise Q3 2026 results audiocast. My name is Mari Reponen, and I am responsible for strategy and IR here at Sitowise. And today with me are our act…
Orthex, Webcast, Q3'26
Language: English11/5/2026, 9:00 AM
Alexander Rosenlew Good morning and welcome to the Orthex Interim Report. My name is Alexander Rosenlew and with me I have Saara Mäkelä, CFO, and Hanna Kukkonen, our CMSO. We will take you through the…
Suominen Oyj, Q3'26
Language: English11/5/2026, 8:30 AM
Anni Luoma Good morning, everyone, and welcome to the Suominen Q3 webcast. My name is Anni Luoma. I am the Manager of External Communications and Investor Relations at Suominen. Here with me are our P…
Lumo, Webcast, Q3'26
Language: English11/5/2026, 8:00 AM
Niina Saarto Good morning, all. Welcome. This is Lumo Homes plc's third quarter result webcast. I am Niina Saarto from Treasury and Investor Relations. Today I have two gentlemen here with me, namely…
CapMan, Webcast, Q3'26
Language: English11/5/2026, 7:30 AM
Charlotte Good morning and welcome to this presentation of CapMan. Q3 2026 interim report. Presenting today we have Pia Kåll, CEO of CapMan. And after the presentation, we will have a Q&A session. You…
Marimekko, Webcast, Q3'26
Language: English11/4/2026, 12:00 PM
Anna Good afternoon. My name is Anna and I am the IRO of Marimekko. It is my pleasure to welcome you to our Q3 webcast. With me, I have our president and CEO, Tiina Alahuhta, who will walk you through…
Administer, Webcast, Q3'26
Language: Finnish11/4/2026, 9:00 AM
Kimmo Herranen Welcome to the Administer Q3 2026 interim report. Results. Meillä on se alkaa. I am Kimmo Herranen. Kalle Lehtonen. Also. Kaarina og. Yelken. Kalle Lehtonen En el coco. Madan. Parannus.…
Kempower, Webcast, Q3'26
Language: English11/4/2026, 8:30 AM
Unknown 1 Powering the planet. Kempower. We charge our planet for the better. By powering the electric movement. We enable quick and scalable EV charging solutions for everyone and everywhere. We ma…